WO1998000130A2 - Anticonvulsant sulfamate derivatives useful in treating obesity - Google Patents
Anticonvulsant sulfamate derivatives useful in treating obesity Download PDFInfo
- Publication number
- WO1998000130A2 WO1998000130A2 PCT/US1997/010953 US9710953W WO9800130A2 WO 1998000130 A2 WO1998000130 A2 WO 1998000130A2 US 9710953 W US9710953 W US 9710953W WO 9800130 A2 WO9800130 A2 WO 9800130A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- treating obesity
- compounds
- alkyl
- derivatives useful
- Prior art date
Links
- 0 CC1C(*)C(*)(*)*CC1* Chemical compound CC1C(*)C(*)(*)*CC1* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- NAKAMURA S. TAMURA
- T. KANDA A. ISHII, K. ISHIHARA
- SERIKAWA J. YAMADA
- M. SASA Eur. J. Pharmacol. Z 83-89, 1994
- A. WAUQUIER and S. ZHOU Epilepsy Res. 2A, 73-77, 1996
- Ri , R2, R3, R4 and R5 are as defined hereinafter are useful in treating obesity.
- X is CH2 or oxygen
- Ri is hydrogen or alkyl
- R3, 4 and R5 are independently hydrogen or lower alkoxy, when X is oxygen, R2 and R3 and/or R4 and R5 together may be a methylenedioxy group of the following formula (II):
- R6 and R7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
- Ri in particular is hydrogen or alkyl of about 1 to 4 carbons, such as methyl, ethyl and iso-propyl.
- Alkyl throughout this specification includes straight and branched chain alkyl.
- R6 and R7 are of about 1 to 3 carbons and include methyl, ethyl, iso-propyl and n-propyl.
- a particular group of compounds of formula (I) are those wherein X is oxygen and both R2 and R3, and R4 and R5 together are methylenedioxy groups of the formula (II), wherein Re and R7 are both hydrogen, both alkyl, or combine to form a spiro cyclopentyl or cyclohexyl ring, in particular where R6 and R7 are both alkyl such as methyl.
- a second group of compounds are those wherein X is CH2 and R4 and R5 are joined to form a benzene ring.
- a third group of compounds of formula (I) are those wherein both R2 and R3 are hydrogen.
- the compounds of formula (I) may be synthesized by the following methods:
- the chlorosulfate of the formula RCH2OSO2CI may then be reacted with an amine of the formula Ri NH2 at a temperature of abut 40° to 25° C in a solvent such as methylene chloride or acetonitrile to produce a compound of formula (I).
- a solvent such as methylene chloride or acetonitrile
- the starting materials of the formula RCH2OH may be obtained commercially or as known in the art.
- starting materials of the formula RCH2OH wherein both R2 and R3, and R4 and R5 are identical and are of the formula (II) may be obtained by the method of R. F. Brady in Carbohydrate Research, Vol. 14, p. 35 to 40 (1970) or by reaction of the trimethylsilyl enol ether of a R6COR7 ketone or aldehyde with fructose at a temperature of about 25° C, in a solvent such a halocarbon, e.g. methylene chloride in the presence of a protic acid such as hydrochloric acid or a Lewis Acid such as zinc chloride.
- the trimethylsilyl enol ether reaction is described by G. L Larson et al in J. Org. Chem. Vol. 38, No. 22, p. 3935 (1973).
- carboxylic acids and aldehydes of the formulae RCOOH and RCHO may be reduced to compounds of the formula RCH2OH by standard reduction techniques, e.g. reaction with lithium aluminum hydride, sodium borohydride or borane-THF complex in an inert solvent such a diglyme, THF or toluene at a temperature of about 0° to 100° C, e.g. as described by H.O. House in "Modern Synthetic Reactions", 2nd Ed., pages 45 to 144 (1972).
- standard reduction techniques e.g. reaction with lithium aluminum hydride, sodium borohydride or borane-THF complex in an inert solvent such a diglyme, THF or toluene at a temperature of about 0° to 100° C, e.g. as described by H.O. House in "Modern Synthetic Reactions", 2nd Ed., pages 45 to 144 (1972).
- the compounds of formula I may also be made by the process disclosed US Patent: No.4,513,006, which is incorporated by reference herein.
- the compounds of formula I include the various individual isomers as well as the racemates thereof, e.g., the various alpha and beta attachments, i.e., below and above the plane of the drawing, of R2, R3, R4 and R5 on the 6- membered ring.
- the oxygens of the methylenedioxy group (II) are attached on the same side of the 6-membered ring.
- a compound of formula (I) may be employed at a daily dosage in the range of about 50 to 200 mg, usually in two divided doses, for an average adult human.
- a unit dose would contain about 25 to 100 mg of the active ingredient.
- one or more sulfamate compounds of formula (I) are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, by suppository, or parenteral.
- a pharmaceutical carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, by suppository, or parenteral.
- any of the usual pharmaceutical media may be employed.
- suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. Suppositories may be prepared, in which case cocoa butter could be used as the carrier.
- the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
- injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- Topiramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent.
- the tablets contain the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.
- compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder injection, teaspoonful, suppository and the like from about 25 to about 200 mg of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002258893A CA2258893C (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity |
APAP/P/1998/001429A AP1285A (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity. |
IL12771597A IL127715A (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity |
AU39578/97A AU732923B2 (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity |
UA98126944A UA53655C2 (en) | 1996-06-28 | 1997-06-23 | Method for treating obesity |
DK97936939T DK0915697T3 (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in the treatment of obesity |
CZ19984278A CZ293876B6 (en) | 1996-06-28 | 1997-06-23 | Medicament useful in treating obesity |
SK1805-98A SK284305B6 (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity |
NZ333586A NZ333586A (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives, preferably topiramate, useful in treating obesity |
BR9710994-0A BR9710994A (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant derivatives useful in the treatment of obesity. |
HU0001192A HU226775B1 (en) | 1996-06-28 | 1997-06-23 | The use of topiramate and its derivatives for preparation of pharmaceutical compositions useful for treating obesity or for weight loss |
EP97936939A EP0915697B1 (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity |
AT97936939T ATE224189T1 (en) | 1996-06-28 | 1997-06-23 | ANTICONVULSIVE SULFAMATE DERIVATIVES FOR THE TREATMENT OF OBESITY |
SI9730421T SI0915697T1 (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity |
DE69715631T DE69715631T2 (en) | 1996-06-28 | 1997-06-23 | ANTI-CONVULSIVE SULFAMATE DERIVATIVES FOR THE TREATMENT OF OBESITY |
JP10504244A JP2000514425A (en) | 1996-06-28 | 1997-06-23 | Sulfamate derivatives of anticonvulsants useful for the treatment of obesity |
NO19986052A NO317754B1 (en) | 1996-06-28 | 1998-12-22 | Anticonvulsant sulphamate derivatives for use in the treatment of obesity |
HK99103712A HK1018743A1 (en) | 1996-06-28 | 1999-08-27 | Anticonvulsant sulfamate derivatives useful in treating obesity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2200496P | 1996-06-28 | 1996-06-28 | |
US60/022,004 | 1996-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998000130A2 true WO1998000130A2 (en) | 1998-01-08 |
WO1998000130A3 WO1998000130A3 (en) | 1998-02-12 |
Family
ID=21807338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/010953 WO1998000130A2 (en) | 1996-06-28 | 1997-06-23 | Anticonvulsant sulfamate derivatives useful in treating obesity |
Country Status (24)
Country | Link |
---|---|
US (1) | US6071537A (en) |
EP (1) | EP0915697B1 (en) |
JP (1) | JP2000514425A (en) |
CN (1) | CN1106193C (en) |
AP (1) | AP1285A (en) |
AT (1) | ATE224189T1 (en) |
AU (1) | AU732923B2 (en) |
BR (1) | BR9710994A (en) |
CA (1) | CA2258893C (en) |
CZ (1) | CZ293876B6 (en) |
DE (1) | DE69715631T2 (en) |
DK (1) | DK0915697T3 (en) |
ES (1) | ES2184127T3 (en) |
HK (1) | HK1018743A1 (en) |
HU (1) | HU226775B1 (en) |
IL (1) | IL127715A (en) |
NO (1) | NO317754B1 (en) |
NZ (1) | NZ333586A (en) |
PT (1) | PT915697E (en) |
RU (1) | RU2214241C2 (en) |
SK (1) | SK284305B6 (en) |
UA (1) | UA53655C2 (en) |
WO (1) | WO1998000130A2 (en) |
ZA (1) | ZA975772B (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050020A2 (en) * | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000061139A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in reducing blood glucose levels |
WO2000061140A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
WO2000061137A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
WO2000061136A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering blood pressure |
WO2002003984A2 (en) * | 2000-07-07 | 2002-01-17 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
US6462084B1 (en) | 2001-05-14 | 2002-10-08 | Brookhaven Science Associates, Llc | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
JP2003524623A (en) * | 1999-04-08 | 2003-08-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant drug derivatives useful for lowering blood glucose levels |
US6890951B2 (en) | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
US6946243B2 (en) | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US9633575B2 (en) | 2012-06-06 | 2017-04-25 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
US10238647B2 (en) | 2003-04-29 | 2019-03-26 | Nalpropion Pharmaceuticals, Inc. | Compositions for affecting weight loss |
US10322121B2 (en) | 2010-01-11 | 2019-06-18 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
US11324741B2 (en) | 2008-05-30 | 2022-05-10 | Nalpropion Pharmaceuticals Llc | Methods for treating visceral fat conditions |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7056890B2 (en) * | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7553818B2 (en) * | 1999-06-14 | 2009-06-30 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7659256B2 (en) * | 1999-06-14 | 2010-02-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
DE10035227A1 (en) * | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
DK1333887T3 (en) * | 2000-10-30 | 2006-11-13 | Ortho Mcneil Pharm Inc | Combination therapy including antidiabetic and anticonvulsant agents |
EP1345602B1 (en) | 2000-11-30 | 2010-07-21 | Novodermix International Limited | Wound healing |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
EP1494998A2 (en) | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
MXPA04011203A (en) * | 2002-05-17 | 2005-07-14 | Univ Duke | Method for treating obesity. |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
IL165383A0 (en) * | 2002-06-21 | 2006-01-15 | Transform Pharmaceuticals Inc | Pharmaceutical compositions with improved dissolution |
US7208477B2 (en) * | 2002-12-02 | 2007-04-24 | University Of Florida Research Foundation, Inc. | Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases |
US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US6949518B1 (en) | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
EP1734955A2 (en) | 2004-01-13 | 2006-12-27 | Duke University | Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
WO2005107806A1 (en) * | 2004-04-21 | 2005-11-17 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
CA2565154A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
TW200612905A (en) * | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
EA010977B1 (en) * | 2004-08-24 | 2008-12-30 | Янссен Фармацевтика Н.В. | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
ES2402522T3 (en) | 2005-11-22 | 2013-05-06 | Orexigen Therapeutics, Inc. | Compositions and procedures to increase insulin sensitivity |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US20070191453A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction |
US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
US20070191461A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine |
US20070191449A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression |
US20070191459A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
KR20170077291A (en) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | Unit dosage packages |
KR101735466B1 (en) | 2006-11-09 | 2017-05-15 | 오렉시젠 세러퓨틱스 인크. | Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138441A2 (en) * | 1983-09-26 | 1985-04-24 | McNeilab, Inc. | Anticonvulsant sulfamate derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4586916A (en) * | 1985-01-30 | 1986-05-06 | Consolidated Papers, Inc. | Corrugated carton separator |
US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
-
1997
- 1997-06-23 ES ES97936939T patent/ES2184127T3/en not_active Expired - Lifetime
- 1997-06-23 CA CA002258893A patent/CA2258893C/en not_active Expired - Lifetime
- 1997-06-23 NZ NZ333586A patent/NZ333586A/en not_active IP Right Cessation
- 1997-06-23 EP EP97936939A patent/EP0915697B1/en not_active Expired - Lifetime
- 1997-06-23 SK SK1805-98A patent/SK284305B6/en not_active IP Right Cessation
- 1997-06-23 BR BR9710994-0A patent/BR9710994A/en not_active IP Right Cessation
- 1997-06-23 RU RU98123575/14A patent/RU2214241C2/en active
- 1997-06-23 JP JP10504244A patent/JP2000514425A/en not_active Ceased
- 1997-06-23 WO PCT/US1997/010953 patent/WO1998000130A2/en active IP Right Grant
- 1997-06-23 DE DE69715631T patent/DE69715631T2/en not_active Expired - Lifetime
- 1997-06-23 CN CN97195909A patent/CN1106193C/en not_active Expired - Lifetime
- 1997-06-23 AP APAP/P/1998/001429A patent/AP1285A/en active
- 1997-06-23 CZ CZ19984278A patent/CZ293876B6/en not_active IP Right Cessation
- 1997-06-23 HU HU0001192A patent/HU226775B1/en unknown
- 1997-06-23 DK DK97936939T patent/DK0915697T3/en active
- 1997-06-23 IL IL12771597A patent/IL127715A/en not_active IP Right Cessation
- 1997-06-23 AU AU39578/97A patent/AU732923B2/en not_active Expired
- 1997-06-23 US US08/881,009 patent/US6071537A/en not_active Expired - Lifetime
- 1997-06-23 AT AT97936939T patent/ATE224189T1/en active
- 1997-06-23 UA UA98126944A patent/UA53655C2/en unknown
- 1997-06-23 PT PT97936939T patent/PT915697E/en unknown
- 1997-06-27 ZA ZA975772A patent/ZA975772B/en unknown
-
1998
- 1998-12-22 NO NO19986052A patent/NO317754B1/en not_active IP Right Cessation
-
1999
- 1999-08-27 HK HK99103712A patent/HK1018743A1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138441A2 (en) * | 1983-09-26 | 1985-04-24 | McNeilab, Inc. | Anticonvulsant sulfamate derivatives |
Non-Patent Citations (3)
Title |
---|
B. E. MARYANOFF ET AL: "Anticonvulsant O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(1-methylidene)-beta-D-fruct opyranose Sulfamate and Related Compounds " JOURNAL OF MEDICINAL CHEMISTRY, vol. 30, 1987, pages 880-887, XP000647869 cited in the application * |
ILO E. LEPPIK: "Antiepileptic Drugs in Development: Prospects for the Near Future" EPILEPSIA, vol. 35, no. S4, 1994, USA, pages S29-S40, XP002045945 * |
S. D. SHORVON: "Safety of Topiramate: Adverse Events and Relationships to Dosing " EPILEPSIA, vol. 37, no. Supp. 2, 1996, USA, pages S18-S22, XP002045946 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890951B2 (en) | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
WO2000050020A2 (en) * | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000050020A3 (en) * | 1999-02-24 | 2000-12-21 | Univ Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
CN100548290C (en) * | 1999-02-24 | 2009-10-14 | 辛辛那提大学 | Sulfamate derivatives is used for the treatment of the purposes of impulse control disorder |
US6323236B2 (en) | 1999-02-24 | 2001-11-27 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000061137A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
US6191163B1 (en) | 1999-04-08 | 2001-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering lipids |
WO2000061136A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in lowering blood pressure |
JP2002541199A (en) * | 1999-04-08 | 2002-12-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant derivatives useful for lowering lipids |
JP2003524623A (en) * | 1999-04-08 | 2003-08-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant drug derivatives useful for lowering blood glucose levels |
JP4709392B2 (en) * | 1999-04-08 | 2011-06-22 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant derivatives useful for lowering blood glucose levels |
WO2000061139A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in reducing blood glucose levels |
WO2000061140A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in maintaining weight loss |
US6362220B1 (en) | 1999-04-08 | 2002-03-26 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in reducing blood glucose levels |
JP2004510700A (en) * | 2000-07-07 | 2004-04-08 | オーソーマクニール ファーマシューティカル,インコーポレイテッド | Antispasmodic derivatives useful for preventing progression of type II diabetes and X syndrome |
US6852701B2 (en) | 2000-07-07 | 2005-02-08 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X |
JP4920163B2 (en) * | 2000-07-07 | 2012-04-18 | オーソーマクニール ファーマシューティカル, インコーポレイテッド | Antispasmodic derivatives useful for preventing progression of type II diabetes and syndrome X |
US7109174B2 (en) | 2000-07-07 | 2006-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for preventing the development of type II diabetes mellitus and syndrome X |
WO2002003984A3 (en) * | 2000-07-07 | 2003-03-06 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
WO2002003984A2 (en) * | 2000-07-07 | 2002-01-17 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
US6946243B2 (en) | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
US7238470B2 (en) | 2000-07-20 | 2007-07-03 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting obesity |
US7282325B2 (en) | 2000-07-20 | 2007-10-16 | Solvay Pharmaceuticals Gmbh | Method of preparing pharmaceutical compositions |
US6462084B1 (en) | 2001-05-14 | 2002-10-08 | Brookhaven Science Associates, Llc | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
US10238647B2 (en) | 2003-04-29 | 2019-03-26 | Nalpropion Pharmaceuticals, Inc. | Compositions for affecting weight loss |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
US11324741B2 (en) | 2008-05-30 | 2022-05-10 | Nalpropion Pharmaceuticals Llc | Methods for treating visceral fat conditions |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US10322121B2 (en) | 2010-01-11 | 2019-06-18 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
US9633575B2 (en) | 2012-06-06 | 2017-04-25 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
US10403170B2 (en) | 2012-06-06 | 2019-09-03 | Nalpropion Pharmaceuticals, Inc. | Methods of treating overweight and obesity |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0915697B1 (en) | Anticonvulsant sulfamate derivatives useful in treating obesity | |
CA2258895C (en) | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders | |
US6362220B1 (en) | Anticonvulsant derivatives useful in reducing blood glucose levels | |
US6201010B1 (en) | Anticonvulsant derivatives useful in lowering blood pressure | |
US6191163B1 (en) | Anticonvulsant derivatives useful in lowering lipids | |
US20020052325A1 (en) | Anticonvulsant derivatives useful in maintaining weight loss | |
EP1143917B1 (en) | Anticonvulsant derivatives useful in treating post traumatic stress disorder | |
WO2000023059A2 (en) | Use of anticonvulsant derivatives for treating alcohol dependency | |
EP0964681B1 (en) | Anticonvulsant derivatives useful in treating psoriasis | |
WO1998000129A9 (en) | Anticonvulsant derivatives useful in treating psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97195909.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PV1998-4278 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2258893 Country of ref document: CA Ref document number: 2258893 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 333586 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980710673 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 180598 Country of ref document: SK Ref document number: 1199801091 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/1999/000181 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997936939 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997936939 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-4278 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980710673 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997936939 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1998-4278 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980710673 Country of ref document: KR |